Gentium S.p.A.
GENT today announced that it has submitted a New Drug
Application to the United States Food and Drug Administration for
Defibrotide for the treatment of hepatic veno-occlusive disease in
adults and children undergoing hematopoietic stem-cell transplantation.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
